Work starts on new therapy to prevent Type 1 diabetes

April 27, 2012
Work starts on new therapy to prevent Type 1 diabetes

Scientists at King’s College London have launched a project to develop a new therapy for Type 1 diabetes.  It is hoped the therapy will control the autoimmune responses that underlie the inflammation that leads to diabetes and prevent it from developing. 

Type 1 diabetes affects approximately 290,000 people in the UK, predominantly children and young adults, and incidence in Europe and North America is increasing. There is currently no known cure or effective prevention and treatment requires multiple, daily, lifelong insulin injections.

The project at King’s College London, as part of King’s Health Partners Academic Health Sciences Centre, is the culmination of drug discovery efforts in the Department of Immunobiology and will be supported by a Translation Award of £2.3 million from the Wellcome Trust. 

The team will develop a drug called MultiPepT1De, made from a ‘cocktail’ of peptides, in a strategy known as peptide immunotherapy. 

The autoimmune response in targets specific peptides in the β-cells that make insulin, leading to inflammation, loss of β-cells and complete insulin deficiency. By introducing selected fragments of key proteins from β-cells in a form that switches off inflammation, it is hoped this will ‘re-set’ the immune system. 

The King’s group has identified several of the key peptides involved in this process and will develop these as a therapeutic that counters the immune attack on β-cells but leaves the rest of the immune system intact. The project will focus on the physico-chemical, immunological and toxicological properties of the β-cell peptides. The project is expected to complete in 2014, with early clinical trials to follow.

Professor Mark Peakman from King’s College London said: ‘MultiPepT1De has some important advantages over current approaches to the prevention of Type 1 diabetes, especially its ability to avoid global immune suppression which is a problem with several other approaches under consideration. 

‘Peptide immunotherapy is being explored in other diseases, such as allergies and multiple sclerosis, using cocktails of peptides and shows considerable promise and potential for long-lasting effects. We have pinpointed the key peptides involved in Type 1 diabetes, and are hopeful that this could lead to an effective preventative treatment for children and adults who may be at risk of developing the condition. 

‘The Translation Award from the Wellcome Trust is an exciting opportunity to develop the drug all the way through to testing in volunteers in 2014.’ 

Dr Mike Shaw, Director of IP and Licensing at King’s commented: 'This new funding enables us to continue progressing efficiently towards positioning the technology for clinical trials. New data emerging from the work together with the suite of intellectual property and patents in which King’s has invested for a number of years provides a solid basis from which commercial partners can work with us to see the therapy developed for patient benefit.’ 

Explore further: Childhood intelligence linked to long-term sick leave

Related Stories

Childhood intelligence linked to long-term sick leave

April 13, 2012
(Medical Xpress) -- Individuals with better cognitive function in childhood are less likely to end up on long-term sick leave in adult life, according to new research by the Institute of Psychiatry at King’s College ...

DNA tags key to brain changes in mental disorders

February 27, 2012
(Medical Xpress) -- Researchers from the Institute of Psychiatry at King’s College London have found a relationship between molecular tags on our DNA and the weight of a particular region of the human brain called the ...

Scientists shed new light on link between 'killer cells' and diabetes

January 15, 2012
Killer T-cells in the human body which help protect us from disease can inadvertently destroy cells that produce insulin, new research has uncovered.

Patient-practitioner partnerships not yet realistic

December 16, 2011
(Medical Xpress) -- Much more work must be done to reduce the gap between the policy ideal and the practical reality of shared decision-making between patients and clinicians, according to new research from King’s College ...

Cancer Research UK launches trial of new drug to treat acute childhood leukaemia

January 27, 2012
Cancer Research UK’s Drug Development Office has opened the first trial of a new type of drug to treat children aged from six months to 18 years with acute leukaemia, who are no longer responding to treatment.

Recommended for you

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.